The effects of intermittent prebypass heparin dosing in patients undergoing coronary artery bypass grafting

Area of Science:

• Cardiology
• Anesthesiology
• Hematology

Background:

• Maintaining adequate anticoagulation during cardiopulmonary bypass (CPB) is crucial for patient safety.
• Standard heparin dosing protocols may not consistently provide optimal anticoagulation throughout CPB.
• Variations in heparin efficacy can impact perioperative hemostasis and outcomes.

Purpose of the Study:

• To compare the efficacy of intermittent prebypass heparin dosing versus a standard single dose in maintaining anticoagulation during CPB.
• To evaluate the impact of different heparin dosing strategies on hemostatic markers and blood loss.
• To assess the overall perioperative hemostatic response and anticoagulant monitoring.

Main Methods:

• A comparative study involving two groups of 10 patients each undergoing CPB.
• Group B received three intermittent heparin doses (100 IU/kg) prebypass; Group A received a single standard dose (300 IU/kg).
• Perioperative coagulation tests and point-of-care monitoring were used to assess anticoagulation and hemostasis, correlated with blood loss.

Main Results:

• Fewer patients in the intermittent heparin group (Group B) required additional heparin during CPB (3 vs. 6).
• Group B demonstrated significantly lower reductions in factor VIII, fibrinogen, antithrombin III, and platelet counts during bypass.
• The intermittent heparin group required fewer red blood cell transfusions postoperatively (1 unit vs. 4 units).

Conclusions:

• Intermittent prebypass heparin dosing is more effective in maintaining anticoagulation during CPB.
• This dosing strategy improves hemostatic balance and reduces the need for blood product transfusion.
• Optimized heparin administration can lead to better perioperative outcomes in patients undergoing cardiac surgery.